Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

By G. Ronco, P. Giorgi-Rossi, F. Carozzi, M. Confortini, P. Dalla Palma, A. Del Mistro, B. Ghiringhello, S. Girlando, Anna Gillio-Tos, Laura De Marco and 8 more. The Lancet Oncology, 2010

923 citations recorded by the source corpus.

Subfields: Epidemiology, Obstetrics and Gynecology, Statistics and Probability

View Paper: https://www.semanticscholar.org/paper/d2225e7bed06518e50228a6492d7101deb6bed74

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. F. Bray
2. Silvia Franceschi
3. J. Ferlay
4. S. de Sanjosé
5. G. Clifford
6. M. Arbyn
7. X. Castellsagué
8. A. Jemal

In Obstetrics and Gynecology

1. G. Clifford
2. Silvia Franceschi
3. S. de Sanjosé

In Statistics and Probability

1. F. Bray
2. M. Arbyn

Citations in the corpus

• Worldwide burden of cervical cancer in 2008. (2011, background): “In Europe, four randomised trials consistently showed, in the second screening round, a significant reduction of CIN3+ (cervical intraepithelial neoplasia of grade III or worse) by screening with a validated HPV assay compared with cytology [45], and one trial showed even a significant reduction in ”
• Human papillomavirus types in 115,789 HPV‐positive women: A meta‐analysis from cervical infection to cancer (2012, background): “glandular lesions and cervical adenocarcinoma (ADC),(23) which are known to be less efficiently detected and prevented by cytological screening.(5,6,24) Nevertheless, ADC constituted less than 10% of all ICCs in the present analysis (and only 3% of African ICC, where the enrichment of HPV45 in ICC w”